It’s not about the high. Artificially derived cannabis products can treat glaucoma and chronic pain without the trouble and expense of growing marijuana plants, which would shift the turf of clashes over medical pot. Now epilepsy drug Epidiolex is on the verge of federal approval, though it would require a long-awaited downgrade of marijuana from a Schedule 1 drug before it could be prescribed. While cannabis biotech is seeing a flood of investment, don’t expect products to bum-rush the market. Given how long FDA approvals take, backers will have to chill.